Sativex Review: Effective Across Multiple Pain Conditions Without Tolerance or Withdrawal
Clinical assessment of Sativex (THC:CBD spray) demonstrated efficacy across intractable neuropathic pain, brachial plexus injury pain, advanced cancer pain, rheumatoid arthritis, and MS symptoms, without significant intoxication, tolerance, or withdrawal syndrome.
Quick Facts
What This Study Found
This review covered the clinical development of Sativex as a combined cannabinoid medicine (THC and CBD) delivered via oromucosal spray. The spray delivery system was designed to maintain therapeutic levels while minimizing psychoactive effects.
Sativex had been shown to be well tolerated and successfully self-administered and self-titrated in both healthy volunteers and patient cohorts. Clinical trials demonstrated efficacy across a range of conditions: intractable chronic neuropathic pain, brachial plexus nerve injury pain, allodynic peripheral neuropathic pain, advanced cancer pain, rheumatoid arthritis, and MS symptoms (bladder problems, spasticity, central pain).
Notably, trials reported no significant intoxication-like symptoms, no development of tolerance, and no withdrawal syndrome upon discontinuation.
Key Numbers
Conditions with demonstrated efficacy: intractable neuropathic pain, brachial plexus injury pain, allodynic neuropathic pain, advanced cancer pain, rheumatoid arthritis, MS bladder problems, MS spasticity, MS central pain. No significant intoxication, tolerance, or withdrawal reported.
How They Did This
Clinical review of Sativex development program covering pharmacology, delivery system, healthy volunteer studies, and clinical trials across multiple pain and neurological conditions.
Why This Research Matters
The absence of tolerance, withdrawal, and significant intoxication addressed three major concerns about cannabis-based medicines. If patients can use a cannabinoid medicine long-term without needing escalating doses or experiencing withdrawal when stopping, it makes the treatment more practical and reduces concerns about dependence.
The Bigger Picture
The combination of THC and CBD in Sativex was intentional: CBD may mitigate some of THC's psychoactive effects while contributing its own therapeutic properties. The broad range of pain conditions showing benefit positions Sativex as a versatile analgesic option.
What This Study Doesn't Tell Us
This review was written from a perspective favorable to the product. Individual trials for some conditions had small sample sizes. The absence of tolerance and withdrawal may partly reflect the relatively short duration of most trials. The optimistic framing may not capture all safety concerns.
Questions This Raises
- ?Does the absence of tolerance persist with very long-term use?
- ?How does Sativex compare head-to-head with established analgesics for each condition?
- ?Does the THC:CBD ratio explain the apparent absence of significant intoxication?
Trust & Context
- Key Stat:
- No significant intoxication, tolerance, or withdrawal syndrome reported across Sativex clinical trials
- Evidence Grade:
- Clinical review of multiple trials. Provides a useful overview but some individual trials had small samples, and the favorable perspective may not capture all safety nuances.
- Study Age:
- Published in 2006. Sativex has since accumulated extensive real-world use data across 25+ countries, generally supporting these efficacy and safety findings.
- Original Title:
- Combined cannabinoid therapy via an oromucosal spray.
- Published In:
- Drugs of today (Barcelona, Spain : 1998), 42(8), 495-503 (2006)
- Authors:
- Perez, Jordi(2)
- Database ID:
- RTHC-00240
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does Sativex cause a high?
Clinical trials reported no significant intoxication-like symptoms with Sativex. The combination of THC with CBD, and the self-titrating spray delivery, appear to minimize psychoactive effects while maintaining therapeutic benefit.
Does Sativex cause dependence or withdrawal?
No withdrawal syndrome or development of tolerance was reported in the clinical trials reviewed. However, most trials were of relatively short duration, and very long-term effects may differ.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00240APA
Perez, Jordi. (2006). Combined cannabinoid therapy via an oromucosal spray.. Drugs of today (Barcelona, Spain : 1998), 42(8), 495-503.
MLA
Perez, Jordi. "Combined cannabinoid therapy via an oromucosal spray.." Drugs of today (Barcelona, 2006.
RethinkTHC
RethinkTHC Research Database. "Combined cannabinoid therapy via an oromucosal spray." RTHC-00240. Retrieved from https://rethinkthc.com/research/perez-2006-combined-cannabinoid-therapy-via
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.